PIM
ITCI

Perkins Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Perkins Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$569K Hold
35,000
– – 0.01% 222
2016
Q4 		$528K Buy
+35,000
New +$494K 0.01% 221

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Perkins Investment Management's ITCI Position: Q1 2017 in Review

Perkins Investment Management held its Intra-Cellular Therapies Inc. (ITCI) position steady in Q1 2017 at 35,000 shares worth $569K. The position accounts for 0.01% of the portfolio, ranked #222.

Perkins Investment Management first reported a position in ITCI in Q4 2016 and has held it in 2 quarters since. 117 funds tracked by Wall St. Rank hold ITCI as of Q1 2017.

  • Perkins Investment Management held 35,000 shares of Intra-Cellular Therapies Inc. worth $569K as of Q1 2017.
  • Perkins Investment Management left its Intra-Cellular Therapies Inc. share count unchanged in Q1 2017.
  • Intra-Cellular Therapies Inc. made up 0.01% of Perkins Investment Management's portfolio in Q1 2017, its #222 holding.
  • Perkins Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and has held it in 2 quarters since.
  • 117 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2017.

Based on Perkins Investment Management's 13F filing for Q1 2017, filed 15 May 2017.